한글목차

처방약 시장 규모는 최근 급성장하고 있습니다. 2025년 1조 4,303억 달러에서 2026년에는 1조 5,860억 2,000만 달러에 이르고, CAGR 10.9%의 성장이 전망되고 있습니다. 지난 몇 년간의 성장 요인으로는 제약 제조 능력 확대, 만성질환 유병률 증가, 브랜드 의약품 포트폴리오 확대, 의료비 지출 증가, 병원 내 의약품 조제 확대 등을 꼽을 수 있습니다.

처방약 시장 규모는 향후 몇 년간 급성장이 전망됩니다. 2030년에는 2조 3,683억 9,000만 달러에 이르고, CAGR은 10.5%를 나타낼 전망입니다. 예측 기간 동안의 성장 요인으로는 비용 효율적인 제네릭 의약품에 대한 수요 증가, 바이오시밀러 도입 확대, 디지털 처방 플랫폼의 확대, 개인 맞춤형 의료에 대한 관심 증가, 시장 간 규제 조화의 진전 등을 꼽을 수 있습니다. 예측 기간의 주요 동향으로는 전문 처방약의 채택 증가, 제네릭 의약품 대체품에 대한 수요 증가, 만성질환 관리에 대한 관심 증가, 생물학적 제제 및 바이오시밀러 치료의 확대, 의약품 안전에 대한 규제 감시 강화 등이 있습니다.

향후 몇 년 동안 의약품 생산량 증가가 처방약 시장의 성장을 견인할 것으로 예측됩니다. 의약품 생산은 품질, 안전성, 유효성을 확보하기 위해 제제화, 시험, 포장 등 의약품의 제조 공정을 체계적으로 수행하는 것을 말합니다. 의약품 생산량 증가는 전 세계 의약품 수요 증가에 대응하고, 공중보건 문제를 해결하고, 다양한 질병에 대한 치료제를 적시에 제공하기 위해 필수적입니다. 의약품 생산의 강화는 처방약 시장공급 안정성, 경제성, 혁신 촉진으로 이어져 궁극적으로 필수 의약품에 대한 접근성 향상과 건강 상태 개선을 통해 환자와 의료 시스템에 이익을 가져다 줄 수 있습니다. 예를 들어, 2025년 10월, 벨기에에 본부를 둔 제약업계 단체인 유럽제약협회(EFPIA)는 유럽 제약산업은 2023년 4,380억 달러(4,057억 유로)에서 2024년 4,750억 달러(4,400억 유로)로 생산량이 크게 증가할 것으로 예상했습니다. 증가했다고 보고했습니다. 따라서 의약품 생산량 증가는 처방약 시장의 발전을 촉진할 것입니다.

처방약 시장의 주요 기업들은 2형 당뇨병 관리 옵션을 개선하기 위해 빅토자(리라글루티드)와 유사한 GLP-1 수용체 작용제 치료제를 대체할 수 있는 대안을 개발하고 있습니다. 빅토자는 GLP-1 수용체 작용제 리라글루티드를 함유한 브랜드명 처방약으로, 주로 성인과 10세 이상의 소아 및 청소년의 2형 당뇨병 관리에 사용됩니다. 예를 들어, 2024년 6월 이스라엘에 본사를 둔 테바 파마슈티컬스(Teva Pharmaceuticals)가 빅토자(리라글루티드 주사제 1.8mg)의 제네릭 의약품을 출시했습니다. 이는 오리지널 브랜드 제품과 동일한 제형, 효능, 품질을 유지하면서 보다 합리적인 가격의 대안을 제공합니다. 이번 출시는 필수적인 당뇨병 치료에 대한 접근성을 개선하고, 2형 당뇨병을 관리하고 심혈관계 질환에 따른 심혈관 위험을 줄이기 위한 비용 효율적인 옵션을 제공하기 위한 것입니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 공급망 분석

제4장 세계 시장 동향과 전략

제5장 최종 이용 산업 시장 분석

제6장 시장 : 금리, 인플레이션, 지정학, 무역 전쟁과 관세의 영향, 관세 전쟁과 무역 보호주의의 공급망에 대한 영향, 코로나 팬데믹이 시장에 미치는 영향을 포함한 거시경제 시나리오

제7장 세계 전략 분석 프레임워크, 현재 시장 규모, 시장 비교 및 성장률 분석

제8장 TAM(Total Addressable Market) 규모

제9장 시장 세분화

제10장 지역별/국가별 분석

제11장 아시아태평양 시장

제12장 중국 시장

제13장 인도 시장

제14장 일본 시장

제15장 호주 시장

제16장 인도네시아 시장

제17장 한국 시장

제18장 대만 시장

제19장 동남아시아 시장

제20장 서유럽 시장

제21장 영국 시장

제22장 독일 시장

제23장 프랑스 시장

제24장 이탈리아 시장

제25장 스페인 시장

제26장 동유럽 시장

제27장 러시아 시장

제28장 북미 시장

제29장 미국 시장

제30장 캐나다 시장

제31장 남미 시장

제32장 브라질 시장

제33장 중동 시장

제34장 아프리카 시장

제35장 시장 규제 상황과 투자환경

제36장 경쟁 구도와 기업 개요

제37장 기타 주요 기업 및 혁신 기업

제38장 세계 시장 경쟁 벤치마킹과 대시보드

제39장 주요 인수합병(M&A)

제40장 시장 잠재력이 높은 국가, 부문, 전략

제41장 부록

영문목차

Prescription drugs are medications that can only be legally obtained with a valid prescription from a licensed healthcare provider. These drugs are used to treat, manage, or prevent various medical conditions, and are prescribed and monitored by healthcare professionals to ensure proper use and minimize the risk of misuse or adverse effects.

Prescription drugs are mainly categorized into branded and generic types. Branded prescription drugs are medications marketed under a proprietary, trademarked name given by the pharmaceutical company that develops and patents the drug. The routes of administration for these drugs include oral, topical, parenteral, and others, and they are used in therapy areas such as oncology, immunology, ophthalmology, respiratory, dermatology, gastroenterology, urology, gynecology, endocrinology, and more. End users of prescription drugs include hospitals, specialty clinics, homecare, and others.

Tariffs are impacting the prescription drugs market by increasing costs of imported active pharmaceutical ingredients, excipients, packaging materials, and manufacturing equipment used in branded and generic drug production. Pharmaceutical manufacturers and hospitals in North America and Europe are most affected due to globalized supply chains, while Asia-Pacific faces export-related pricing pressure. These tariffs are increasing production costs and affecting drug pricing structures. However, they are also promoting domestic API manufacturing, regional supply chain diversification, and increased investment in local pharmaceutical production facilities.

The prescription drugs market research report is one of a series of new reports from The Business Research Company that provides prescription drugs market statistics, including prescription drugs industry global market size, regional shares, competitors with a prescription drugs market share, detailed prescription drugs market segments, market trends and opportunities, and any further data you may need to thrive in the prescription drugs industry. This prescription drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The prescription drugs market size has grown rapidly in recent years. It will grow from $1430.3 billion in 2025 to $1586.02 billion in 2026 at a compound annual growth rate (CAGR) of 10.9%. The growth in the historic period can be attributed to expansion of pharmaceutical manufacturing capacity, rising prevalence of chronic diseases, growth of branded drug portfolios, increasing healthcare expenditure, expansion of hospital-based drug dispensing.

The prescription drugs market size is expected to see rapid growth in the next few years. It will grow to $2368.39 billion in 2030 at a compound annual growth rate (CAGR) of 10.5%. The growth in the forecast period can be attributed to increasing demand for cost-effective generics, rising adoption of biosimilars, expansion of digital prescription platforms, growing focus on personalized drug therapies, increasing regulatory harmonization across markets. Major trends in the forecast period include increasing adoption of specialty prescription drugs, rising demand for generic drug alternatives, growing focus on chronic disease management, expansion of biologic and biosimilar therapies, enhanced regulatory oversight of drug safety.

The growing production of drugs is expected to drive the growth of the prescription drug market in the coming years. Drug production involves the organized process of creating pharmaceutical products, including their formulation, testing, and packaging, to ensure quality, safety, and effectiveness. Increasing drug production is essential to meet the rising global demand for medications, address public health challenges, and ensure the timely availability of treatments for various medical conditions. Enhanced drug production can improve the availability, affordability, and innovation in the prescription drug market, ultimately benefiting patients and the healthcare system by improving access to essential medications and supporting better health outcomes. For example, in October 2025, the European Federation of Pharmaceutical Industries and Associations (EFPIA), a Belgium-based organization representing the pharmaceutical sector, reported significant growth in the European pharmaceutical industry, with production rising from $438 billion (€405.7 billion) in 2023 to $475 billion (€440 billion) in 2024. Therefore, the increase in drug production will drive the development of the prescription drug market.

Leading companies in the prescription drug market are developing alternatives to Victoza (liraglutide) or similar GLP-1 receptor agonist therapies to offer improved options for managing type 2 diabetes. Victoza is a brand-name prescription medication containing liraglutide, a GLP-1 receptor agonist, primarily used to manage type 2 diabetes in adults and children aged 10 years and older. For example, in June 2024, Teva Pharmaceuticals, an Israel-based company, launched an authorized generic of Victoza (liraglutide injection 1.8 mg), providing a more affordable alternative while maintaining the same formulation, efficacy, and quality as the original branded product. This launch aims to improve access to essential diabetes treatments, offering cost-effective options for managing type 2 diabetes and reducing cardiovascular risks associated with the condition.

In December 2023, Bristol Myers Squibb, a US-based pharmaceutical company, acquired Karuna Therapeutics for $14 billion. With this acquisition, Bristol Myers Squibb aims to strengthen its neuroscience portfolio by integrating Karuna's novel cholinergic-based therapies, including KarXT, and expanding its pipeline of treatments for schizophrenia and Alzheimer's disease psychosis. Karuna Therapeutics is a US-based biopharmaceutical company focused on developing prescription drugs for neuroscience disorders.

Major companies operating in the prescription drugs market are Pfizer Inc., Johnson & Johnson Private Limited, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Allergan plc, Bayer AG, Novartis AG, Sanofi SA, Bristol-Myers Squibb Company, AstraZeneca Plc, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Boehringer Ingelheim International GmbH, Gilead Sciences Inc, Amgen Inc., Viatris Inc., Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Biogen Inc., Sun Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories Ltd., Hikma Pharmaceuticals PLC, Lupin Limited

North America was the largest region in the prescription drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the prescription drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the prescription drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The prescription drugs market consists of sales of bronchodilators, corticosteroids, combination inhalers, antibiotics, mucolytics, and biologics. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Prescription Drugs Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses prescription drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for prescription drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The prescription drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Type: Branded; Generics
• 2) By Route Of Administration: Oral; Topical; Parenteral; Other Routes Of Administration
• 3) By Therapy Area: Oncology; Immunology; Ophthalmology; Respiratory; Dermatology; Gastroenterology; Urology; Gynecology; Endocrinology; Other Therapy Areas
• 4) By End-Users: Hospitals; Specialty Clinics; Homecare; Other End-Users
• Subsegments:
• 1) By Branded: Innovative Drugs; Patented Drugs; Blockbuster Drugs; Over-the-Counter (OTC) Prescription Drugs; Biosimilars; Specialty Drugs; Orphan Drugs; Combination Drugs
• 2) By Generics: Small Molecule Generics; Generic Biologics; Over-the-Counter (OTC) Generics; Authorized Generics; Generic Combination Drugs; High-Volume Generics; Generic Versions Of Blockbuster Drugs
• Companies Mentioned: Pfizer Inc.; Johnson & Johnson Private Limited; F. Hoffmann-La Roche Ltd.; Merck & Co. Inc.; AbbVie Inc.; Allergan plc; Bayer AG; Novartis AG; Sanofi SA; Bristol-Myers Squibb Company; AstraZeneca Plc; GlaxoSmithKline plc; Takeda Pharmaceutical Company Limited; Eli Lilly and Company; Boehringer Ingelheim International GmbH; Gilead Sciences Inc; Amgen Inc.; Viatris Inc.; Teva Pharmaceutical Industries Ltd.; Astellas Pharma Inc.; Biogen Inc.; Sun Pharmaceutical Industries Ltd.; Dr. Reddy's Laboratories Ltd.; Hikma Pharmaceuticals PLC; Lupin Limited
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.

Table of Contents

1. Executive Summary

• 1.1. Key Market Insights (2020-2035)
• 1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots
• 1.3. Major Factors Driving the Market
• 1.4. Top Three Trends Shaping the Market

2. Prescription Drugs Market Characteristics

• 2.1. Market Definition & Scope
• 2.2. Market Segmentations
• 2.3. Overview of Key Products and Services
• 2.4. Global Prescription Drugs Market Attractiveness Scoring And Analysis
  • 2.4.1. Overview of Market Attractiveness Framework
  • 2.4.2. Quantitative Scoring Methodology
  • 2.4.3. Factor-Wise Evaluation
• Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation
• 2.4.4. Market Attractiveness Scoring and Interpretation
• 2.4.5. Strategic Implications and Recommendations

3. Prescription Drugs Market Supply Chain Analysis

• 3.1. Overview of the Supply Chain and Ecosystem
• 3.2. List Of Key Raw Materials, Resources & Suppliers
• 3.3. List Of Major Distributors and Channel Partners
• 3.4. List Of Major End Users

4. Global Prescription Drugs Market Trends And Strategies

• 4.1. Key Technologies & Future Trends
  • 4.1.1 Digitalization, Cloud, Big Data & Cybersecurity
  • 4.1.2 Biotechnology, Genomics & Precision Medicine
  • 4.1.3 Artificial Intelligence & Autonomous Intelligence
  • 4.1.4 Industry 4.0 & Intelligent Manufacturing
  • 4.1.5 Fintech, Blockchain, Regtech & Digital Finance
• 4.2. Major Trends
  • 4.2.1 Increasing Adoption Of Specialty Prescription Drugs
  • 4.2.2 Rising Demand For Generic Drug Alternatives
  • 4.2.3 Growing Focus On Chronic Disease Management
  • 4.2.4 Expansion Of Biologic And Biosimilar Therapies
  • 4.2.5 Enhanced Regulatory Oversight Of Drug Safety

5. Prescription Drugs Market Analysis Of End Use Industries

• 5.1 Hospitals
• 5.2 Specialty Clinics
• 5.3 Retail Pharmacies
• 5.4 Online Pharmacies
• 5.5 Homecare Providers

6. Prescription Drugs Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Prescription Drugs Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

• 7.1. Global Prescription Drugs PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 7.2. Global Prescription Drugs Market Size, Comparisons And Growth Rate Analysis
• 7.3. Global Prescription Drugs Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
• 7.4. Global Prescription Drugs Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Prescription Drugs Total Addressable Market (TAM) Analysis for the Market

• 8.1. Definition and Scope of Total Addressable Market (TAM)
• 8.2. Methodology and Assumptions
• 8.3. Global Total Addressable Market (TAM) Estimation
• 8.4. TAM vs. Current Market Size Analysis
• 8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Prescription Drugs Market Segmentation

• 9.1. Global Prescription Drugs Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Branded, Generics
• 9.2. Global Prescription Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Oral, Topical, Parenteral, Other Routes Of Administration
• 9.3. Global Prescription Drugs Market, Segmentation By Therapy Area, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Oncology, Immunology, Ophthalmology, Respiratory, Dermatology, Gastroenterology, Urology, Gynecology, Endocrinology, Other Therapy Areas
• 9.4. Global Prescription Drugs Market, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Hospitals, Specialty Clinics, Homecare, Other End-Users
• 9.5. Global Prescription Drugs Market, Sub-Segmentation Of Branded, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Innovative Drugs, Patented Drugs, Blockbuster Drugs, Over-the-Counter (OTC) Prescription Drugs, Biosimilars, Specialty Drugs, Orphan Drugs, Combination Drugs
• 9.6. Global Prescription Drugs Market, Sub-Segmentation Of Generics, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Small Molecule Generics, Generic Biologics, Over-the-Counter (OTC) Generics, Authorized Generics, Generic Combination Drugs, High-Volume Generics, Generic Versions Of Blockbuster Drugs

10. Prescription Drugs Market Regional And Country Analysis

• 10.1. Global Prescription Drugs Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• 10.2. Global Prescription Drugs Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Prescription Drugs Market

• 11.1. Asia-Pacific Prescription Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 11.2. Asia-Pacific Prescription Drugs Market, Segmentation By Type, Segmentation By Route Of Administration, Segmentation By Therapy Area, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Prescription Drugs Market

• 12.1. China Prescription Drugs Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 12.2. China Prescription Drugs Market, Segmentation By Type, Segmentation By Route Of Administration, Segmentation By Therapy Area, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Prescription Drugs Market

• 13.1. India Prescription Drugs Market, Segmentation By Type, Segmentation By Route Of Administration, Segmentation By Therapy Area, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Prescription Drugs Market

• 14.1. Japan Prescription Drugs Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 14.2. Japan Prescription Drugs Market, Segmentation By Type, Segmentation By Route Of Administration, Segmentation By Therapy Area, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Prescription Drugs Market

• 15.1. Australia Prescription Drugs Market, Segmentation By Type, Segmentation By Route Of Administration, Segmentation By Therapy Area, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia Prescription Drugs Market

• 16.1. Indonesia Prescription Drugs Market, Segmentation By Type, Segmentation By Route Of Administration, Segmentation By Therapy Area, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea Prescription Drugs Market

• 17.1. South Korea Prescription Drugs Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 17.2. South Korea Prescription Drugs Market, Segmentation By Type, Segmentation By Route Of Administration, Segmentation By Therapy Area, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan Prescription Drugs Market

• 18.1. Taiwan Prescription Drugs Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 18.2. Taiwan Prescription Drugs Market, Segmentation By Type, Segmentation By Route Of Administration, Segmentation By Therapy Area, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia Prescription Drugs Market

• 19.1. South East Asia Prescription Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 19.2. South East Asia Prescription Drugs Market, Segmentation By Type, Segmentation By Route Of Administration, Segmentation By Therapy Area, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe Prescription Drugs Market

• 20.1. Western Europe Prescription Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 20.2. Western Europe Prescription Drugs Market, Segmentation By Type, Segmentation By Route Of Administration, Segmentation By Therapy Area, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK Prescription Drugs Market

• 21.1. UK Prescription Drugs Market, Segmentation By Type, Segmentation By Route Of Administration, Segmentation By Therapy Area, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany Prescription Drugs Market

• 22.1. Germany Prescription Drugs Market, Segmentation By Type, Segmentation By Route Of Administration, Segmentation By Therapy Area, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France Prescription Drugs Market

• 23.1. France Prescription Drugs Market, Segmentation By Type, Segmentation By Route Of Administration, Segmentation By Therapy Area, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy Prescription Drugs Market

• 24.1. Italy Prescription Drugs Market, Segmentation By Type, Segmentation By Route Of Administration, Segmentation By Therapy Area, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain Prescription Drugs Market

• 25.1. Spain Prescription Drugs Market, Segmentation By Type, Segmentation By Route Of Administration, Segmentation By Therapy Area, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe Prescription Drugs Market

• 26.1. Eastern Europe Prescription Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 26.2. Eastern Europe Prescription Drugs Market, Segmentation By Type, Segmentation By Route Of Administration, Segmentation By Therapy Area, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia Prescription Drugs Market

• 27.1. Russia Prescription Drugs Market, Segmentation By Type, Segmentation By Route Of Administration, Segmentation By Therapy Area, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America Prescription Drugs Market

• 28.1. North America Prescription Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 28.2. North America Prescription Drugs Market, Segmentation By Type, Segmentation By Route Of Administration, Segmentation By Therapy Area, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA Prescription Drugs Market

• 29.1. USA Prescription Drugs Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 29.2. USA Prescription Drugs Market, Segmentation By Type, Segmentation By Route Of Administration, Segmentation By Therapy Area, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada Prescription Drugs Market

• 30.1. Canada Prescription Drugs Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 30.2. Canada Prescription Drugs Market, Segmentation By Type, Segmentation By Route Of Administration, Segmentation By Therapy Area, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America Prescription Drugs Market

• 31.1. South America Prescription Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 31.2. South America Prescription Drugs Market, Segmentation By Type, Segmentation By Route Of Administration, Segmentation By Therapy Area, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil Prescription Drugs Market

• 32.1. Brazil Prescription Drugs Market, Segmentation By Type, Segmentation By Route Of Administration, Segmentation By Therapy Area, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East Prescription Drugs Market

• 33.1. Middle East Prescription Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 33.2. Middle East Prescription Drugs Market, Segmentation By Type, Segmentation By Route Of Administration, Segmentation By Therapy Area, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa Prescription Drugs Market

• 34.1. Africa Prescription Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 34.2. Africa Prescription Drugs Market, Segmentation By Type, Segmentation By Route Of Administration, Segmentation By Therapy Area, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. Prescription Drugs Market Regulatory and Investment Landscape

36. Prescription Drugs Market Competitive Landscape And Company Profiles

• 36.1. Prescription Drugs Market Competitive Landscape And Market Share 2024
  • 36.1.1. Top 10 Companies (Ranked by revenue/share)
• 36.2. Prescription Drugs Market - Company Scoring Matrix
  • 36.2.1. Market Revenues
  • 36.2.2. Product Innovation Score
  • 36.2.3. Brand Recognition
• 36.3. Prescription Drugs Market Company Profiles
  • 36.3.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.2. Johnson & Johnson Private Limited Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.3. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.4. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.5. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis

37. Prescription Drugs Market Other Major And Innovative Companies

• Allergan plc, Bayer AG, Novartis AG, Sanofi SA, Bristol-Myers Squibb Company, AstraZeneca Plc, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Boehringer Ingelheim International GmbH, Gilead Sciences Inc, Amgen Inc., Viatris Inc., Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc.

38. Global Prescription Drugs Market Competitive Benchmarking And Dashboard

39. Key Mergers And Acquisitions In The Prescription Drugs Market

40. Prescription Drugs Market High Potential Countries, Segments and Strategies

• 40.1 Prescription Drugs Market In 2030 - Countries Offering Most New Opportunities
• 40.2 Prescription Drugs Market In 2030 - Segments Offering Most New Opportunities
• 40.3 Prescription Drugs Market In 2030 - Growth Strategies
  • 40.3.1 Market Trend Based Strategies
  • 40.3.2 Competitor Strategies

41. Appendix

• 41.1. Abbreviations
• 41.2. Currencies
• 41.3. Historic And Forecast Inflation Rates
• 41.4. Research Inquiries
• 41.5. The Business Research Company
• 41.6. Copyright And Disclaimer